MarkL.SundermeyerMD

Oncology • Saint Louis, MO

Breast Cancer, Gastrointestinal Cancer, Genitourinary Oncology

Associate Professor

Join to view full profile

Dr. Sundermeyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sundermeyer's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Fax+1 314-362-3192

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Temple University HospitalResidency, Internal Medicine, 2000 - 2003
University of Missouri-Columbia School of MedicineClass of 2000

Certifications & Licensure

MO State Medical License 2023 - 2026
OR State Medical License 2020 - 2025
WA State Medical License 2021 - 2024
PA State Medical License 2001 - 2021
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Philadelphia Magazine Top Doctor Philadelphia Magazine, 2018-2020
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Publications & Presentations

PubMed

23 citations
Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base
Alina M. Mateo, Todd A. Pezzi, Mark L. Sundermeyer, Cynthia A. Kelley, V. Suzanne Klimberg
Annals of Surgical Oncology. 2017-04-01
9 citations
Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data...
Alina M. Mateo, Todd A. Pezzi, Mark L. Sundermeyer, Cynthia A. Kelley, Vicki Klimberg
Journal of Surgical Oncology. 2016-10-01
8 citations
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Naveed Ali, Faizan Malik, Syed Imran Mustafa Jafri, Mary Naglak, Mark L. Sundermeyer
Clinical Lymphoma, Myeloma & Leukemia. 2016-09-01

Press Mentions

Scarpaci Joins Abington Cancer Care SpecialistsJanuary 13th, 2016